QLS4131

· Qilu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for QLS4131, covering 2024-07-15 to 2025-06-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus [Phase 1]